These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27789778)

  • 21. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
    Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.
    Hu X; Zhang L; Shi Y; Zhou C; Liu X; Wang D; Song Y; Li Q; Feng J; Qin S; Xv N; Zhou J; Zhang L; Hu C; Zhang S; Luo R; Wang J; Tan F; Wang Y; Ding L; Sun Y
    PLoS One; 2015; 10(11):e0142500. PubMed ID: 26599904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
    Li X; Yang XJ; Sun YF; Qin N; Lü JL; Wu YH; Zhang H; Zhang Q; Zhang SC
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):627-31. PubMed ID: 23159001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
    Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of the Efficacy and Safety of Icotinib with Standard Second-line 
Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer].
    Yao S; Qian K; Wang R; Li Y; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):369-73. PubMed ID: 26104894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N; Zhang Q; Fang S; Han X; Wang Z
    Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
    Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
    Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical Analysis of Icotinib on Beneficiary of 
Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].
    Jiang X; Wang W; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):200-6. PubMed ID: 27118647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
    Tan F; Shi Y; Wang Y; Ding L; Yuan X; Sun Y
    Future Oncol; 2015; 11(3):385-97. PubMed ID: 25675121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
    Gong L; Xiong M; Huang Z; Miao L; Fan Y
    Lung Cancer; 2015 Sep; 89(3):268-73. PubMed ID: 26141219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride].
    Nong J; Qin N; Wang J; Yang X; Zhang H; Wu Y; Lv J; Zhang Q; Zhang S
    Zhongguo Fei Ai Za Zhi; 2013 May; 16(5):240-5. PubMed ID: 23676980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution.
    Xu J; Liu X; Yang S; Zhang X; Shi Y
    Asia Pac J Clin Oncol; 2017 Dec; 13(6):379-384. PubMed ID: 28276163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
    Yang G; Yao Y; Zhou J; Zhao Q
    Oncol Rep; 2012 Jun; 27(6):2066-72. PubMed ID: 22446631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
    J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
    Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
    J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
    Soria JC; Baselga J; Hanna N; Laurie SA; Bahleda R; Felip E; Calvo E; Armand JP; Shepherd FA; Harbison CT; Berman D; Park JS; Zhang S; Vakkalagadda B; Kurland JF; Pathak AK; Herbst RS
    Eur J Cancer; 2013 May; 49(8):1815-24. PubMed ID: 23490650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
    Zhao Q; Wang YN; Wang B
    Jpn J Clin Oncol; 2013 Feb; 43(2):200-4. PubMed ID: 23264674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
    Fan Y; Xu Y; Gong L; Fang L; Lu H; Qin J; Han N; Xie F; Qiu G; Huang Z
    Sci Rep; 2017 Mar; 7():45193. PubMed ID: 28332624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.
    Guan Y; Zhao H; Meng J; Yan X; Jiao S
    Lung Cancer; 2014 Feb; 83(2):305-7. PubMed ID: 24370197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.